Matches in SemOpenAlex for { <https://semopenalex.org/work/W2333326120> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2333326120 endingPage "409" @default.
- W2333326120 startingPage "403" @default.
- W2333326120 abstract "Identifying the abuse potential of drug products in the premarketing and postmarketing environment has been a critical component in the implementation of drug abuse control laws worldwide. In the US, the Controlled Substances Act of 1970 (CSA) is a comprehensive federal law enacted to prevent the abuse or diversion of substances with abuse liability or addiction potential (for present purposes, these terms are used interchangeably). Under the jurisdiction of the Drug Enforcement Administration, the law applies to the manufacture and distribution of narcotics and other drug substances with potential of abuse. The CSA classifies substances with abuse potential into schedules I–V based on the substance’s risk of diversion or abuse, and thus provides a legal framework for the assessment of abuse liability of New Molecular Entities. When the Food and Drug Administration reviews the safety and efficacy of a New Drug Application it also determines whether the drug has potential for abuse, and if so, will begin the process to schedule the drug under the CSA. As the assessment of abuse potential is a critical component of a marketing application, pharmaceutical companies (sponsors) bear the responsibility of generating a comprehensive preclinical and clinical data package for regulators to review and make decisions on labeling and the corresponding postmarketing surveillance. Recent regulatory guidelines adopted in the European Union (EU) (2006), Canada (2007), and USA (2010) provide recommendations to sponsors on preclinical and clinical methodologies for the assessment of abuse potential. This paper reviews the legal framework of the assessment of abuse liability and scheduling of controlled substances in the USA and describes the current global regulatory environment and the challenges that sponsors and regulators face when assessing abuse liability of New Molecular Entities, from the early stages of development through the late stages, review, and approval." @default.
- W2333326120 created "2016-06-24" @default.
- W2333326120 creator A5087503761 @default.
- W2333326120 date "2013-09-01" @default.
- W2333326120 modified "2023-09-24" @default.
- W2333326120 title "Principles of assessment of abuse liability" @default.
- W2333326120 cites W1966462692 @default.
- W2333326120 cites W1999877037 @default.
- W2333326120 cites W2017949829 @default.
- W2333326120 doi "https://doi.org/10.1097/fbp.0b013e328363d163" @default.
- W2333326120 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23820327" @default.
- W2333326120 hasPublicationYear "2013" @default.
- W2333326120 type Work @default.
- W2333326120 sameAs 2333326120 @default.
- W2333326120 citedByCount "15" @default.
- W2333326120 countsByYear W23333261202013 @default.
- W2333326120 countsByYear W23333261202014 @default.
- W2333326120 countsByYear W23333261202015 @default.
- W2333326120 countsByYear W23333261202016 @default.
- W2333326120 countsByYear W23333261202017 @default.
- W2333326120 countsByYear W23333261202019 @default.
- W2333326120 countsByYear W23333261202021 @default.
- W2333326120 countsByYear W23333261202022 @default.
- W2333326120 crossrefType "journal-article" @default.
- W2333326120 hasAuthorship W2333326120A5087503761 @default.
- W2333326120 hasConcept C112930515 @default.
- W2333326120 hasConcept C118552586 @default.
- W2333326120 hasConcept C121955636 @default.
- W2333326120 hasConcept C144133560 @default.
- W2333326120 hasConcept C17744445 @default.
- W2333326120 hasConcept C199539241 @default.
- W2333326120 hasConcept C2776949292 @default.
- W2333326120 hasConcept C2777834853 @default.
- W2333326120 hasConcept C2779777834 @default.
- W2333326120 hasConcept C2780035454 @default.
- W2333326120 hasConcept C3018251022 @default.
- W2333326120 hasConcept C40010229 @default.
- W2333326120 hasConcept C71924100 @default.
- W2333326120 hasConcept C98274493 @default.
- W2333326120 hasConceptScore W2333326120C112930515 @default.
- W2333326120 hasConceptScore W2333326120C118552586 @default.
- W2333326120 hasConceptScore W2333326120C121955636 @default.
- W2333326120 hasConceptScore W2333326120C144133560 @default.
- W2333326120 hasConceptScore W2333326120C17744445 @default.
- W2333326120 hasConceptScore W2333326120C199539241 @default.
- W2333326120 hasConceptScore W2333326120C2776949292 @default.
- W2333326120 hasConceptScore W2333326120C2777834853 @default.
- W2333326120 hasConceptScore W2333326120C2779777834 @default.
- W2333326120 hasConceptScore W2333326120C2780035454 @default.
- W2333326120 hasConceptScore W2333326120C3018251022 @default.
- W2333326120 hasConceptScore W2333326120C40010229 @default.
- W2333326120 hasConceptScore W2333326120C71924100 @default.
- W2333326120 hasConceptScore W2333326120C98274493 @default.
- W2333326120 hasIssue "5 and 6" @default.
- W2333326120 hasLocation W23333261201 @default.
- W2333326120 hasLocation W23333261202 @default.
- W2333326120 hasOpenAccess W2333326120 @default.
- W2333326120 hasPrimaryLocation W23333261201 @default.
- W2333326120 hasRelatedWork W1598182626 @default.
- W2333326120 hasRelatedWork W2102339174 @default.
- W2333326120 hasRelatedWork W2264095370 @default.
- W2333326120 hasRelatedWork W2353605121 @default.
- W2333326120 hasRelatedWork W250306860 @default.
- W2333326120 hasRelatedWork W2613762130 @default.
- W2333326120 hasRelatedWork W2767134993 @default.
- W2333326120 hasRelatedWork W2811405620 @default.
- W2333326120 hasRelatedWork W2896781993 @default.
- W2333326120 hasRelatedWork W3124166674 @default.
- W2333326120 hasVolume "24" @default.
- W2333326120 isParatext "false" @default.
- W2333326120 isRetracted "false" @default.
- W2333326120 magId "2333326120" @default.
- W2333326120 workType "article" @default.